BridgeBio Pharma (BBIO) Return on Capital Employed (2019 - 2026)
BridgeBio Pharma recorded quarterly Return on Capital Employed of 155.72% in Q1 2026, down 102.06% quarter-over-quarter from 77.07% in Q4 2025, and down 6250.0% year-over-year from 2.53% in Q1 2025.
BridgeBio Pharma's Return on Capital Employed history runs 8 years deep, the most recent figure standing at 155.72% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 6250.0% year-over-year to 155.72%; the TTM figure through Mar 2026 stood at 155.72% (down 6250.0% YoY), while the FY2025 annual figure was 81.82%, up 2069.0% from the prior year.
- Return on Capital Employed came in at 155.72% for Q1 2026 at BridgeBio Pharma, down from 77.07% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 72.0% in Q1 2022 to a low of 155.72% in Q1 2026.
- A 5-year average of 94.74% and a median of 88.05% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed jumped 4251 bps in 2024 and tumbled 6250 bps in 2026, its largest moves.
- BridgeBio Pharma's Return on Capital Employed stood at 92.38% in 2022, then plunged by 44 bps to 132.95% in 2023, then surged by 30 bps to 92.98% in 2024, then climbed by 17 bps to 77.07% in 2025, then slumped by 102 bps to 155.72% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 155.72%, 77.07%, and 74.14% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn | -155.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -155.72% |
| Dec 31, 2025 | -77.07% |
| Sep 30, 2025 | -74.14% |
| Jun 30, 2025 | -81.54% |
| Mar 31, 2025 | -93.23% |
| Dec 31, 2024 | -92.98% |
| Sep 30, 2024 | -92.19% |
| Jun 30, 2024 | -74.23% |
| Mar 31, 2024 | -86.43% |
| Dec 31, 2023 | -132.95% |
| Sep 30, 2023 | -118.15% |
| Jun 30, 2023 | -116.73% |
| Mar 31, 2023 | -88.05% |
| Dec 31, 2022 | -92.38% |
| Sep 30, 2022 | -81.12% |
| Jun 30, 2022 | -81.69% |
| Mar 31, 2022 | -72.00% |
| Dec 31, 2021 | -75.66% |
| Sep 30, 2021 | -64.44% |
| Jun 30, 2021 | -53.27% |
| Mar 31, 2021 | -67.13% |
| Dec 31, 2020 | -73.00% |
| Sep 30, 2020 | -55.22% |
| Jun 30, 2020 | -42.14% |
| Mar 31, 2020 | -40.89% |
| Dec 31, 2019 | -46.24% |
| Sep 30, 2019 | -89.76% |